Ionis Pharmaceuticals Competitors and Similar CompaniesClear all
Ionis Pharmaceuticals's competitors and similar companies include Bluebird Bio, Arrowhead Pharmaceuticals, Reata Pharmaceuticals, Alnylam Pharmaceuticals, Ultragenyx Pharmaceutical, Lannett, Intellia Therapeutics and Sarepta Therapeutics.
 Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. |  Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. |  Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. |  Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. |  Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases. |  Intellia Therapeutics Intellia is developing therapeutic products to help people with genetic diseases. |  Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. | |||
Founding Date | Founding Date 1989 | Founding Date 1992 | Founding Date 2004 | Founding Date 2002 | Founding Date 2002 | Founding Date 2010 | Founding Date 1942 | Founding Date 2014 | Founding Date 1980 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||||
Locations | Locations Carlsbad, US HQ | Locations Pasadena, US HQ Madison, US San Diego, US | Locations Plano, US HQ Irving, US Plano, US | Locations Novato, US HQ | Locations Trevose, US HQ Philadelphia, US | Locations Cambridge, US HQ | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US | ||
Employees | Employees 7577% decrease | Employees 1,2134% increase | Employees 13416% increase | Employees 22079% increase | Employees 1,32324% increase | Employees 74021% increase | Employees 81015% decrease | Employees 27028% increase | Employees 8403% decrease |
Valuation ($) | Valuation ($) 6.8 b | Valuation ($) 324.1 m | Valuation ($) 3.3 b | Valuation ($) 6.5 b | Valuation ($) 21.9 b | Valuation ($) 2.7 b | Valuation ($) 7.4 m | Valuation ($) 2.8 b | Valuation ($) 11.1 b |
Twitter followers | Twitter followers 4.4 k | Twitter followers 10.6 k | Twitter followers 3.3 k | Twitter followers 1.5 k | Twitter followers 16.3 k | Twitter followers N/A | Twitter followers N/A | Twitter followers 9.3 k | Twitter followers 5 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 5 | Number of tweets (last 30 days) 8 | Number of tweets (last 30 days) 4 | Number of tweets (last 30 days) 10 | Number of tweets (last 30 days) 23 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 7 | Number of tweets (last 30 days) 13 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 4 | Average likes per tweet (last 30 days) 5.1 | Average likes per tweet (last 30 days) 36 | Average likes per tweet (last 30 days) 3.4 | Average likes per tweet (last 30 days) 3 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 23.3 | Average likes per tweet (last 30 days) 40.6 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 75% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 60% | Percentage of tweets with engagement (last 30 days) 86.96% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 69.23% |
Employee Rating | Employee Rating 3.6 | Employee Rating 3.6 | Employee Rating 3.9 | Employee Rating 3.6 | Employee Rating 4.2 | Employee Rating 4.3 | Employee Rating 2.1 | Employee Rating 4 | Employee Rating 4.1 |
Financial | |||||||||
Revenue (est.) | Revenue (est.) $587.4m (FY, 2022) | Revenue (est.) $3.6m (FY, 2022) | Revenue (est.) $243.2m (FY, 2022) | Revenue (est.) $2.2m (FY, 2022) | Revenue (est.) $1b (FY, 2022) | Revenue (est.) $363.3m (FY, 2022) | Revenue (est.) $340.6m (FY, 2022) | Revenue (est.) $52.1m (FY, 2022) | Revenue (est.) $933m (FY, 2022) |
Cost of goods | Cost of goods $14.1m (FY, 2022) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $140.2m (FY, 2022) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $573.3m (FY, 2022) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $897.2m (FY, 2022) | Gross profit N/A | Gross profit $33.2m (FY, 2022) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($269.7m) (FY, 2022) | Net income ($266.6m) (FY, 2022) | Net income ($176.5m) (FY, 2022) | Net income ($311.9m) (FY, 2022) | Net income ($1.1b) (FY, 2022) | Net income ($707.4m) (FY, 2022) | Net income ($231.6m) (FY, 2022) | Net income ($474.2m) (FY, 2022) | Net income ($703.5m) (FY, 2022) |
Operating ⚠ | |||||||||
Patents Issued | Patents Issued N/A | Patents Issued N/A | Patents Issued 359 (FY, 2016) | Patents Issued 240 (FY, 2016) | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A |
Phase I Trials Products | Phase I Trials Products 6 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 24 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 6 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A |
Funding | |||||||||
Total funding raised | Total funding raised N/A | Total funding raised $ 409m | Total funding raised $ 147.1m | Total funding raised $ 468.9m | Total funding raised $ 1.5b | Total funding raised $ 200.1m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Bluebird Bio
HQ
Cambridge, US
Employees
1,213↑ 4% increase
Bluebird Bio is a developer of gene therapies for severe genetic diseases and cancer.
View companyArrowhead Pharmaceuticals
HQ
Pasadena, US
Employees
134↑ 16% increase
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
View companyReata Pharmaceuticals
HQ
Plano, US
Employees
220
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
View companyAlnylam Pharmaceuticals
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
View company